A model integrating deep learning with clinical and epidemiologic data may significantly improve lung cancer risk prediction based on LDCT screening.
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 ...
In this case study, CyPath® Lung “Unlikely Malignancy” result supported physician’s decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasive CyPath® Lung test ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Tempus AI, Inc. TEM recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to ...
Background Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for ...
Please provide your email address to receive an email when new articles are posted on . The main element of RevealAI-Lung is the Malignancy Similarity Index (mSI) score. In a study population of 1,530 ...
An artificial intelligence (AI)-powered tool that characterizes lung nodules has earned clearance from the FDA, according to a press release from manufacturer RevealDx. The RevealAI-Lung software ...
LONDON, 29th January, 2026 (WAM) -- The National Health Service (NHS) England will trial a combination of AI and robot-assisted care to speed up the detection and diagnosis of lung cancer, the UK’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results